T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show if a dose of T-20 added to an anti-HIV combination
(chosen specifically for each patient) lowers viral load by at least a certain level after 24
weeks as compared to an anti-HIV combination (chosen specifically for each patient) alone.
Another purpose is to show if the patient response to T-20 will be maintained for 48 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborator:
Trimeris
Treatments:
Enfuvirtide HIV Protease Inhibitors Protease Inhibitors